MedTrace Logo

A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel to Correct Infraorbital Hollowing

NCT03418545 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2021-11-15

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the safety and effectiveness of JUVÉDERM® VOLBELLA™ XC in adult participants seeking correction of hollowing of the tear troughs.

Conditions

  • Infraorbital Hollowing

Interventions

DEVICE

JUVÉDERM VOLBELLA® XC injectable gel

JUVÉDERM® VOLBELLA™ XC dermal filler injected into the infraorbital and adjacent area.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Steve Abrams · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-26
Primary Completion
2018-10-17
Completion
2019-08-22
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03418545 on ClinicalTrials.gov